Today’s post from Alice is dedicated to Beta-secretase 1, also known as beta-site amyloid precursor protein cleaving enzyme 1 or beta-site APP cleaving enzyme 1 (BACE1).

On the Chemspace website, we added a wide variety of biological products you need for your study. Here is the link where you can find antibodies to BACE, ready-to-use biological kits, proteins, and RNAs.

BACE is a membrane-bound aspartyl protease involved in the production of Alzheimer's disease (AD) Aβ amyloid peptides. This enzyme is ubiquitously expressed, with the highest levels in the brain and pancreas. The amount of BACE is elevated in the brain cortex of AD sufferers, and increased levels of BACE in the cerebrospinal fluid of patients with mild cognitive impairment may provide an early biomarker of AD. It is actively studied as a rational drug target for AD therapy, and inhibitors are under development. To read more visit this link.

BACE inhibitors, which decrease BACE1 (β-secretase 1) cleavage of the amyloid precursor protein, are a potential treatment for Alzheimer’s disease. The approval of Aβ antibody aducanumab increased the enthusiasm for BACE inhibitors, but the side effects are still a concern. It is important to identify the factors underlying the failures in BACE inhibitor clinical trials for a better understanding of the potential alternative AD treatment strategies.